Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDY -1.87%74 Net-Net Working Capital is $-18.19 as of Dec. 2025. GuruFocus rates SHTDY with a GF Score™ of 74/100 and a GF Value™ of $13.60 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 28 Medical Distribution companies, Sinopharm Group Co ranks worse than 3571425% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Sinopharm Group Co's Net-Net Working Capital for the quarter that ended in Dec. 2025 was $-18.19.
The industry rank for Sinopharm Group Co's Net-Net Working Capital or its related term are showing as below:
SHTDY's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Distribution industry.
Industry Median: 6.4 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Sinopharm Group Co (OTCPK:SHTDY) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Sinopharm Group Co Net-Net Working Capital Related Terms
Sinopharm Group Co Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTDY vs MCK, CAH, COR: Net-Net Working Capital Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Price-to-Net-Net-Working-Capital vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $-18.19 mean?
Sinopharm Group Co (SHTDY) has a Net-Net Working Capital of $-18.19 as of Dec. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Sinopharm Group Co According to the industry distribution chart, Sinopharm Group Co ranks #999999 out of 28 companies in the Medical Distribution industry.
Is Sinopharm Group Co's Net-Net Working Capital too high?
Sinopharm Group Co's current Net-Net Working Capital is $-18.19. Based on the distribution chart, Sinopharm Group Co ranks #999999 out of 28 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Net-Net Working Capital compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #999999 out of 28 companies for Net-Net Working Capital. This places Sinopharm Group Co in the lower half of its industry. The industry median Net-Net Working Capital is 6.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Distribution company?
The median Net-Net Working Capital among Medical Distribution companies is 6.40, based on 28 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Sinopharm Group Co For the Medical Distribution industry, the median Net-Net Working Capital is 6.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Net-Net Working Capital is $-18.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.60, compared to a current price of $11.03 — trading 18.9% below its estimated fair value. The current Net-Net Working Capital is $-18.19. Sinopharm Group Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Net-Net Working Capital is $-18.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $11.03 is trading 18.9% below its estimated GF Value™ of $13.60.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
Net-Net Working Capital: $-18.19
GF Value™: $13.60 vs. price of $11.03 (18.9% below fair value)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
74GF Score
Get the complete analysis for SHTDY
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 
